The slip
PARKINSON RECEIPTno. 0999
17 Oct 2026, 11:44 UTCdopamine neurons, braak
predictionSLC6A3 in dopamine neurons tracks Braak Lewy-body stage
registeredf035a70577bd948d
discovery-0.35 p=0.361 n=9
replication-0.41 p=0.273 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.35, p 0.361)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTff19fac57429244a45833d0e…
follows 9df8004ab480…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 0999: SLC6A3 in dopamine neurons, braak
- power
- full sample -0.17 (p 0.498, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.424, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.06, sign flips 0; without severely affected donors -0.17 (p 0.498, n 18). fragile.
- cell type
- strongest in astrocytes: -0.68 (p 0.0020, n 18) vs -0.17 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC6A3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC6A3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.70 p 0.013 (needs p < 0.0013)